Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
124I-PU-AD PET Imaging Pilot
NCT03371420Phase 1Terminated
- Sponsor
- Samus Therapeutics
- Start
- Apr 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 124I-PU-AD in solid malignancy, lymphoma, multiple myeloma (MM) and 1 more, sponsored by Samus Therapeutics. Primary endpoints: Area Under the Curve at 1 week, Maximum Plasma Concentration at 1 week and 3 more. Started Apr 2016; status: terminated.
02
Drugs
124I-PU-AD
03
Conditions
solid malignancylymphomamultiple myeloma (MM)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03371420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03371420.